Development of Human Leukocyte Antigen (HLA) Antibodies Against Vascular Homograft Donor in Pediatric Heart Transplant Recipients by Jahnukainen, Timo et al.
Received: 2019.04.27
Accepted: 2019.06.05
Published: 2019.08.06
Development of Human Leukocyte Antigen 
(HLA) Antibodies Against Vascular Homograft 
Donor in Pediatric Heart Transplant Recipients
 ABCDEFG 1 Timo Jahnukainen
 CDE 2 Jouni Lauronen
 BCDE 3 Alireza Raissadati
 BCDE 3 Jaana I. Pihkala
 BDE 1 Elisa Ylinen
 BCE 4 Juha Tapani Puntila
 BDE 4 Jukka T. Salminen
 BDE 4 Tommi Pätilä
 BCE 4 Ilkka P. Mattila
 ABDEF 1 Hannu Jaakko Jalanko
 Corresponding Author: Timo Jahnukainen, e-mail: timo.jahnukainen@hus.fi
 Source of support: The study has been supported by the Foundation for Pediatric Research and the Sigrid Juselius Foundation
 Background: The appearance of human leukocyte antigen (HLA) antibodies after solid organ transplantation predisposes re-
cipients to graft dysfunction. In theory, vascular homografts, which are widely used in children with congeni-
tal heart defects, may cause allosensitization.
 Material/Methods: In this single-center retrospective study, the presence of pre-existing HLA antibodies in pediatric heart trans-
plant (HTx) recipients with a vascular homograft was evaluated in a cohort of 12 patients. HLA antibodies were 
screened before and after HTx and positive screening results were confirmed and identified using the Luminex® 
single antigen bead method. Endomyocardial biopsies (EMB) and coronary angiography studies were re-eval-
uated to assess the prevalence of acute rejections and coronary artery change in these patients.
 Results: At the time of HTx, 8 patients (67%) had HLA antibodies detected by the Luminex assay, none of which were 
heart donor specific (DSA). All patients had negative leukocyte crossmatch. One patient developed DSAs against 
homograft donor prior to HTx. After the HTx, 5 patients (42%) developed DSAs against the heart donor and 
4 patients (40%) against the homograft donor. In 2 patients (17%), the antibodies were against both heart and 
homograft donors. The rejection rate or prevalence of coronary artery vasculopathy did not differ significantly 
between the homograft cohort and our historical controls.
 Conclusions: Our results suggest that the prevalence of DSAs against homograft donor prior to HTx is relatively rare. However, 
almost half of the patients developed DSAs against homograft post-HTx. The clinical importance of these an-
tibodies warrants further studies.
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Background
Circulating donor-specific HLA antibodies (DSA) have been as-
sociated with increased risk for allograft vasculopathy and im-
paired graft survival in heart transplant (HTx) recipients [1–3]. 
The risk for developing DSAs is increased in patients with pre-
vious heart operations [4,5] and it has been suggested that 
pediatric recipients with congenital heart disease (CHD) have 
worse outcome than patients with cardiomyopathy [6,7]. Recent 
database analyses have established the presence of positive 
(>10%) panel reactive antibodies (PRA) before transplantation 
as a significant risk factor for 1-year mortality among pediat-
ric HTx population [8].
The significance of HLA antibodies induced by vascular allografts 
and valve implants has remained unclear [9–12]. In patients 
with chronic kidney disease, vein allografts from deceased 
donors used for hemodialysis access have been suggested to 
lead to HLA sensitization [13], which may further cause hu-
moral transplant rejection and graft dysfunction [14]. Vascular 
allografts have been used for decades among pediatric patients 
with congenital heart defects and it has been shown previously, 
that approximately 40% to 60% of these children develop HLA 
antibodies after allograft implantation [15–17]. Many of these 
patients with pre-existing HLA sensitization may require HTx 
during childhood or as adults. In the present study, we aimed 
to evaluate the presence of HLA antibodies against vascular 
homograft donor and heart transplant donor before and af-
ter HTx in a cohort of pediatric HTx patients with a vascu-
lar homograft from deceased donors. The long-term survival, 
number of acute rejections, and coronary arterial changes were 
evaluated retrospectively and compared to historical controls. 
We hypothesized that vascular homografts from deceased do-
nors increases the risk for allosensitization before HTx which 
may further lead to increased number of rejections after HTx.
Material and Methods
Patients and patient selection
This is a single-center retrospective study of pediatric HTx re-
cipients with a history of receiving vascular homografts from 
deceased donor at the Children’s Hospital, Helsinki University 
Hospital (ethical approval no. HUS26/2018). Since 2000, HLA 
antibodies have been monitored systematically and the data 
were collected from all pediatric HTx patients transplanted be-
tween January 2000 and December 2015. A total of 44 patients 
underwent pediatric HTx. Seventeen patients had congenital 
heart disease (CHD), including hypoplastic left heart syndrome 
(HLHS) (n=6), univentricular heart (UVH) (n=3), transposition 
of the great arteries (TGA) (n=2), AV discordance (n=2), double 
outlet right ventricle (n=1), and pulmonary and/or tricuspid 
atresia (n=2). All patients with CHD had palliative surgeries 
prior to HTx and in 12 cases (71%), vascular allografts from 
18 deceased donors were used.
Vascular allografts were preserved in dimethyl sulfoxide (DMSO) 
cryopreservant (CryoSure-DMSO, WAK-Chemie) and stored in liq-
uid nitrogen for a maximum of 5 years. Before use, the allografts 
were thawed according to the standard procedure. All vascu-
lar allografts were selected based on ABO blood grouping. 
The vast majority of the homografts consisted of pulmonary 
artery grafts; in 2 patients, aortic graft was used. No immuno-
suppressive medication was used during or after the operation.
The immunosuppressive protocol for all HTx patients consisted 
of anti-thymoglobulin induction therapy and triple medication 
including calcineurin inhibitor, azathioprine, and methylpred-
nisolone (MP). None of the patients were put on immuno-
suppression after receiving of a vascular allograft from a de-
ceased donor.
Data acquisition
The HLA antibody status, number of biopsy proven rejections, 
and coronary angiography findings were analyzed retrospec-
tively from the data collected at routine follow-up visits at 
our center. The follow-up consists of anti-HLA antibody tests 
and endomyocardial biopsies (EMB) at 1, 3, 6, 9, 12, 18, and 
24 months after HTx, and annually thereafter. Coronary angi-
ography is performed annually in patients older than 4 to 5 
years of age. The patients are transferred to adult care at the 
age of 18 to 22 years.
One Lambda Labscreen® mixed with Luminex® was used for 
HLA antibody screening and PRA calculation with the use of 
HLA Fusion software (One Lambda Inc., Canoga Park, CA, USA). 
In case of a positive screening result, the presence of HLA anti-
bodies was confirmed and identified using the Luminex® single 
antigen bead method. A normalized MFI cutoff point of 1000 
was used for positivity in single antigen analyses. Antibodies 
against HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ, and HLA-DP 
were analyzed. These results were compared to the HLA data 
of both vascular allograft donors and heart donors collected 
from the registry of the Finnish Red Cross Blood Service.
Endomyocardial biopsies (EMB) were classified according to the 
ISHLT criteria [18]. Grade 1R finding was defined as immunoacti-
vation. Coronary angiograms were re-evaluated by an experienced 
pediatric cardiologist (JP). The angiography findings were classi-
fied according to the ISHLT guidelines into CAV grades 0–3 [19].
The Research Ethics Committee of Helsinki University Hospital 
approved the study; an informed written consent was obtained 
from all study subjects or their parents.
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Statistical analysis
Numerical data are presented as medians with ranges. 
The Mann-Whitney U test was used to compare patient groups 
with or without history of receiving homograft. Findings were 
considered statistically significant when the probability of 
a chance finding was less than 5% (P<0.05). SPSS version 22.0 
software was used for statistical analysis.
Present study (n=12) Historical CHD (n=29) Historical all (n=68) p-Value*
Female/Male, % 50/50 42/58 53/47 0.873
Operations before HTx, n  3.4±1.2  3.0±1.4  1.4±1.5 1.00
Age at homograft insertion, years  4.0±6.3 NA NA
VAD, n (%)  0  0  6 (9) 1.00
Waiting time, days  125±210  168±223  150±201 0.353
Age at Htx, years  10.8±5.8  9.1±5.4  8.5±5.4 0.320
Follow-up time after HTx, years  5.6±4.7  13.2±8.0  12.7±7.5 0.009
Retransplantations, n (%)  2 (17)  3 (10)  5 (7) 0.620
HLA A/B match, n (%) n=14
 0/4  2 (14)  3 (10)  9 (12) 0.620
 1/4  10 (71)  12 (42)  31 (46) 0.165
 2/4  2 (14)  7 (24)  16 (24) 0.702
 3/4  0 (0)  0 (0)  4 (6)
 4/4  0 (0)  0 (0)  0 (0)
HLA DR match, n (%)
 0/2  6 (43)  8 (28)  27 (40) 0.278
 1/2  6 (43)  10 (34)  25 (37) 0.485
 2/2  2 (14)  4 (14)  8 (12) 1.00
Mortality, n (%)  2 (17)  12 (41)  29 (43) 0.165
Acute cellular rejections
 Patients, n (%)  7 (67) NA NA
 Episodes, n 18 NA 103
CAV at the time of the study n=12 n=22 n=60
 CAV score 0, n (%)  4 (33)  12 (55)  38 (63) 0.410
 CAV score 1, n (%)  2 (17)  2 (9)  4 (7) 0.602
 CAV score 2, n (%)  3 (25)  2 (9)  9 (15) 0.391
 CAV score 3, n (%)  0 (0)  4 (18)  4 (7) 0.273
 NA  3 (25)  2 (9)  5 (8)
Table 1.  Patients’ demographics and characteristics. The table presents data from patients of the present study, from patients with 
congenital heart defect transplanted at our institution, and from all pediatric heart transplant patients at our unit. The data 
have been partly presented by Raissadati et al. [20].
CHD – congenital heart defect; HTx – heart transplant; CAV – coronary artery vasculopathy; CIT – cold ischemia time; VAD – ventricular 
assist device; NA – not available. Values are presented as mean ± standard deviation. * Comparison between present cohort and 
historical CHD patients.
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Results
Patient demographics
Table 1 summarizes patient characteristics of the present 
study in respect to all pediatric HTx patients and patients 
transplanted due to CHD at our institution between 1991 and 
2012 [20]. In the current patient cohort, a mean of 3.4 open 
heart surgeries had been performed prior to HTx. In 10 pa-
tients, vascular allografts from deceased donors were inserted 
a median of 1.37 (0.6–16.2) years prior to HTx. In 1 patient 
(Patient 11), a vascular homograft was inserted at HTx, and 
in another patient (Patient 6), 29 days after the HTx because 
of invasive Candida albicans infection of the aorta (Table 2). 
Vascular homografts from 18 different donors were used and 
HLA data were available from 16 donors (89%). Two patients 
had retransplantation and HLA type was available from all 14 
heart donors. HLA antibodies were followed up according to 
our standard protocol and these data were available from all 
12 patients. In 9 HTx patients, both heart and homograft do-
nors had the same HLA type in a total of 16 alleles (class I, 
n=10 and class II, n=6).
HLA sensitization before HTx
Eight patients (67%) had HLA antibodies (PRA >10%) before 
HTx (Table 2). None of the pre-existing HLA antibodies were 
against heart donor, while 1 patient had DSA (DR1, MFI 2453) 
against the homograft donor. These homograft donor DSAs 
were detected for the first time 13.6 years after insertion of 
the homograft.
HLA sensitization after HTx
After HTx, a total of 7 patients (58%) developed anti-HLA an-
tibodies. The median time from HTx to the first detection of 
DSAs was 69 (13–2865) days. In 5 patients (42%), the anti-
bodies were de novo DSAs against heart donors and in 4 pa-
tients (40%), they were de novo DSAs against homograft do-
nors. In 2 cases (Patient 4 and Patient 9), the post-HTx de novo 
DSAs were against both the heart and the homograft donor 
(Table 3). Patient 4 experienced biopsy-proven antibody-me-
diated rejection 2 weeks after the first HTx and developed se-
vere coronary artery vasculopathy (CAV) later on. She was re-
transplanted 9 years after the first HTx. After the second HTx, 
she developed de novo DQ7 DSA against the heart and ho-
mograft donor (Table 3). In Patient 9, no coronary angiogra-
phy or endomyocardial biopsy was performed because of her 
Patient Age at HTx
Homograft prior 
HTx, years 
Cause of HTx PRA class I/II,% Match class I/II CNI
1 M 6.6 1.4 AS 0/24 1/0 CyA>Tac
2 M 10.2 7.8 TOF 17/0 1/1 CyA>Tac
3 F 1.4 1.4 HLHS 61/87 1/0 CyA
4 F 6.4 5.9 HLHS 75/99 1/0 CyA>Tac
15.7 57/66 1/0 Tac
5 F 10.1 9.7 HLHS 0/+ 1/1 Tac
6 M 15.7 –0.1 TGA 0/0 2/2 Tac
7 M 16.2 16.2 HLHS 10/64 1/1 Tac
8 F 4.5 0.6 TGA 0/9 2/1 Tac
9 F 0.6 0.6 HLHS 52/45 0/0 Tac
10 M 15.3 14.9 HLHS 27/26 0/1 Tac
16.1 0/0 1/2 Tac
11 M 19.2 0.0 HLHS 0/0 1/0 CyA
12 F 13.4 13.4 HLHS 74/99 1/1 Tac
Table 2. Clinical data in each individual patient.
M – Male; F – Female; HTx – heart transplantation; PRA – panel reactive antibody; CNI – calcineurin inhibitor; CyA – cyclosporine A; 
Tac – tacrolimusl CyA>Tac – patient switched from cyclosporine A to tacrolimus; AS – aortic valve stenosis; HLHS – hypoplastic left 
heart syndrome; TOF – tetralogy of Fallot; TGA – transposition of the great arteries.
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young age. She developed 3 different DSA with MFI >4000 
units within 36 days after the HTx.
Rejection rate and angiography findings
Eight patients (67%) had a total of 18 episodes of immuno-
activations or acute rejections (AR). Three ARs (17%) were di-
agnosed within 3 months of HTx and 1 episode was proven 
to be antibody-mediated rejection (AMR). The number of re-
jection episodes per patient did not differ between patients 
with homograft (1.4) and all HTx patients (1.5). Five patients 
(42%) had abnormal coronary angiography finding (CAV1-2), 
while 36% of the historical CHD patients and 29% of all HTx 
patients had at least CAV1 in their angiograms (Table 3). Out 
of 5 patients with ³CAV1, one patient had de novo DSA against 
both the heart and the homograft donor.
Two patients (17%) died: 1 patient died at 3.3 years after HTx 
from acute arrhythmia and another patient died at 2.5 months 
after retransplantation from posttransplant lymphoprolifera-
tive disease and sepsis.
Discussion
Patients with congenital heart defects are known to be at in-
creased risk for developing HLA antibodies prior to heart trans-
plantation [4]. Theoretically, the risk for sensitization is even 
higher in patients with vascular homograft from deceased 
donor and it has been shown that HLA sensitization may last 
several years after the allograft implantation [15,17]. If the 
homograft and heart donor share even partly the same HLA 
genotype, it may increase the risk for antibody-mediated re-
jection and graft dysfunction after HTx. In the present study, 
we show that DMSO-preserved homografts from deceased do-
nors do not pose a significant risk for sensitization in pediat-
ric HTx population. The vast majority of patients in our cohort 
had PRA >10% prior to HTx; with only 1 patient having HLA 
antibodies against the homograft donor and none against the 
heart donor. None of our patients had positive crossmatch in 
the cytotoxic assay at the time of transplantation. Five patients 
developed de novo DSAs post-HTx and in 2 of these patients, 
the DSAs were against both the homograft and the heart donor. 
We could not rule out a causative role of the pre-existing HLA 
Patient
Class I DSA (MFI) Class II DSA (MFI)
AR, n
CAV 
gradusHeart Homograft Heart Homograft
1 No DSA NA No DSA NA 3 2
2 No DSA NA No DSA NA 2 1
3 No DSA No DSA DQ2 (2734) No DSA 1 0
4 No DSA No DSA
DQ6 (5155), 
DQ5 (3780)
DQ6 (2662) 4 2
A3 (4767) A3 (4767), B7 (4550) DR4 (2233)
5 No DSA No DSA No DSA No DSA 4 1
6 No DSA No DSA No DSA No DSA 0 2
7 No DSA B39 (2073) No DSA DR1 (2046) 2 0
8 No DSA No DSA No DSA NA NA
9 A2 (4356) A2 (4356)
DR4 (4428)
DQ7 (4009)
DR4 (4428)
DQ7 (4009)
NA NA
10 A1 (3017), B8 (1183) No DSA DQ7 (1976) No DSA 1 NA
11 No DSA No DSA No DSA 0 0
12 A3 (1297), B51 (1154) No DSA
DR1 (3186), 
DR3 (5733), 
DQ5 (1715), 
DR51 (1560)
1 0
Table 3.  The table shows the presence of donor-specific antibodies against heart donor and homograft donor in each individual 
patient. The number of biopsy proven acute cellular rejections and coronary artery angiography findings classified according 
to the ISHLT guidelines are also presented.
MFI – median fluorescence intensity; AR – acute cellular rejection; CAV – coronary artery vasculopathy; NA – not available; 
DSA – donor-specific antibody.
458
Jahnukainen T. et al.: 
HLA immunization and vascular homograft
© Ann Transplant, 2019; 24: 454-460
ORIGINAL PAPER
Indexed in: [Science Citation Index Expanded] [Index Medicus/MEDLINE] 
[Chemical Abstracts] [Scopus]
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
antibodies in the development of CAV and significant graft 
dysfunction in 1 of the latter patients (Patient 4), however, 
the prevalence of biopsy proven rejections and CAV did not 
differ from historical controls. To the best of our knowledge, 
no previous study reporting the homograft donor DSAs after 
HTx has been published.
According to the previous studies, it is likely that exposure to 
the vascular allograft leads to humoral response and HLA im-
munization [15–17]. Meyers et al. have shown that the use of 
cryopreserved allograft tissue in the Norwood procedure is 
associated with a significant humoral response in the major-
ity of patients, especially in those who were mismatched for 
HLA type [15]. The major concern with HLA antibodies is con-
sequently prolonged waiting times for HTx, increased risk for 
antibody-mediated rejection due to pre-existing HLA antibod-
ies, and dysfunction of the vascular allograft [21]. The data 
about the effect of homograft induced HLA sensitization on 
rejection rate and graft function after HTx are scarce. In pedi-
atric heart transplant recipients, a PRA 10% or more was as-
sociated with increased mortality and rejection rate compared 
with those with a PRA under 10% [5]. Our retrospective analy-
sis on biopsy-proven acute rejection and CAV rate did not re-
veal any statistically significant difference between the HTx 
recipients with vascular allograft and our transplant popula-
tion in general. Our data do not support the initiation of im-
munosuppression for recipients of a vascular allograft from 
deceased donors.
The immunogenicity of the allograft depends on treatment and 
preservation of the graft. Vascular allograft treatment model 
that removes cellular elements leaving only the tissue matrix 
has been developed. These decellularization techniques have 
been shown to reduce the risk for homograft-induced sensiti-
zation compared to DMSO-treated grafts [22]. Cryopreserved 
grafts contain viable endothelial cells, which increases the risk 
for an immunogenic response [23,24]. Despite this recent de-
velopment in the homograft treatment methods, there are hun-
dreds of patients with grafts that were inserted in the 1990s 
when less effective decellularization methods were commonly 
used. In our cohort, 1 patient developed de novo DSA against 
the homograft donor more than 10 years after the operation, 
which should be taken into consideration when preparing pa-
tients for heart transplantation.
The major caveats of the study were the small sample size 
and retrospective nature. However, there were also strengths, 
such as systematic routine follow-up of HLA antibodies, EMBs, 
and coronary angiographies. Data regarding the HLA genotype 
of the homograft and heart donors were also available from 
nearly all participants.
Conclusions
We conclude that the risk for development of HLA antibodies 
prior to HTx is relatively small among patients with vascular 
allograft from deceased donor. Donor-specific HLA antibodies 
against homograft donor might appear after HTx. However, 
the clinical importance of this finding remains to be studied.
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